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inter-monomer coupling within the bc1 dimer [4, 6] has remained
elusive.
Here we have used large-scale molecular dynamics (MD) simula-
tions for tracking the communications within the bc1 of Rhodobacter
sphaeroides. The energy correlation analysis [7] revealed the possible
pathways for transmembrane propagation of information about the
redox state of the ubiqinone molecule in the QN site. Non-equilibrium
MD simulations of the bc1 with ubiquinone or ubisemiquinone in the
QN site, respectively, revealed the possible implication of helix E and
the ef-loop of cytochrome b in the intra-monomeric transmembrane
coupling. The MD simulations with occupied and unoccupied QP site
showed a possible pathway for the inter-monomeric communication
between the two QP sites of a bc1 dimer.
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Coenzyme Q (ubiquinone or Q) is a redox-active lipid essential
for electron and proton transport in the mitochondrial respiratory
chain. Q is also important in the mitochondrial inner membrane
because it serves as an antioxidant and it modulates the function of
the mitochondrial membrane transition pore [1]. Most Coq proteins
which participate in Q biosynthesis are present in a high molecular
mass multi-subunit complex in Saccharomyces cerevisiae. The absence
of a single Coq polypeptide from the complex causes a drastic
diminution of the steady state levels of some Coq proteins. In
consequence, only an early intermediate of the Q biosynthetic
pathway accumulates in Δcoq1–Δcoq9 strains [2].
We report that overexpression of the protein kinase Coq8 restores
the steady state levels of the Coq proteins in most Δcoq strains. The
stabilization of the Coq polypeptides leads to the accumulation of
Q biosynthetic intermediates [3]. These intermediates are likely
not competent to transfer electrons in the respiratory chain because
the strains are not capable of growing on non-fermentable carbon
sources. However, we suggest that some of these Q biosynthetic
intermediates have an antioxidant activity and are therefore able to
redox-cycle in vivo since they diminish the sensitivity of the
accumulating strains to poly-unsaturated fatty acids.
4-hydroxybenzoic acid is the precursor of the aromatic ring of Q.
We demonstrate that analogs of 4-hydroxybenzoic acid can be used
in vivo to either promote the synthesis of analogs of coenzyme Q [4]
or to bypass a deﬁcient Q biosynthetic step. In this later case, the use
of vanillic acid allowed the restoration of Q biosynthesis and
respiration in cells deﬁcient for the monooxygenase Coq6 [5].
Our data illustrate the possibility to generate Q analogs in vivo
which offers the opportunity to study the structural requirements of
Q for its different cellular functions.
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Using a stochastic simulation without any other hypotheses, we
have demonstrated the natural emergence of the Mitchell Q-cycle in
the functioning of the bc1 complex, with few short-circuits and a very
low occupancy of the reactive semiquinone species in the Qo site [1].
However, this simple model fails to explain both the inhibition by
antimycin of the bc1 complex and the accompanying increase in ROS
production.
To obtain inhibition of electron transfer to the high potential chain
in the presence of antimycin, it is necessary to block the electron
transfer from the reduced haem bL to the semiquinone in the Qo site
(short-circuit or bypass of type 2) [2]. Incorporating this constraint in
our stochastic model, we obtain a sigmoid inhibition curve due to the
fact that when only one antimycin is bound per bc1 dimer, the
electron of the inhibited monomer systematically crosses the dimer
interface to reduce a quinone or a semiquinone species in the other
(free) Qi site (bL–bL path). Because this step is not limiting, the
activity is unchanged (compared to the activity of the free dimer).
Interestingly, this bL–bL pathway is almost exclusively taken in this
half-bound antimycin dimmer. In the free dimer, the natural faster
pathway is bL–bH on the same monomer (at least in the absence of
ΔμH+). The addition of the assumption of half-of-the-sites reactivity
to the previous hypothesis leads to a transient activation in the
antimycin titration curve preceding a quasi-complete inhibition at
antimycin saturation.
In accordance with the chemistry of quinone, we have examined
the possibility that the return of the electron from the reduced haem
bL to the semiquinone in Qo could be blocked if we take into account
the protons transfer and release from the Qo site accompanying the
electron transfer. However preliminary simulations show that it is not
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sufﬁcient to completely block this bypass. We are currently trying to
deﬁne more precisely the steps necessarily or possibly involved in the
antimycin inhibition of bc1 complex and their chemical/physical basis
[3].
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Cytochrome bc1 (cyt bc1) is a central enzyme of many respiratory
and photosynthetic systems which couples the proton transport
across the membrane with electron transfer from ubiquinone (Q) to
cytochrome c (cyt c) pool. Cyt bc1 from Rhodobacter capsulatus is
composed of only three catalytically relevant subunits: cytochrome b
(cyt b), cytochrome c1 (cyt c1) and iron–sulfur (FeS) protein. One of
the unique features of the operation of cyt bc1 is a large-scale
movement of FeS head domain, which shuttles electrons between Q
bound at Q-binding site (Qo) at cyt b and cyt c1. We employed the
measurements of the electron longitudinal relaxation of the iron–
sulfur cluster to analyze the efﬁciencies of the relaxation mechanisms
associated with structural changes induced by mutations that lower
the FeS midpoint potential (S158A or Y160W) and/or by the changes
induced during the FeS movement. Low temperature dependence of
the relaxation rates was measured by inversion-recovery at Q-band
and analyzed assuming dominant direct and second-order Raman
processes. In all cases the magnetization recovery was non single
exponential with no signs of the contribution from spectral diffusion.
We found a signiﬁcant decrease in the efﬁciency of the Raman process
(Cram) in the order: Wild Type cyt bc1 (WT)NY160WNS158A which is
in agreement with the theory that predicts a decrease of spin–phonon
coupling with the decrease in g-anisotropy of the paramagnetic
center. However the effect of additional mutations or the addition of
inhibitors, that increase the FeS density at the Qo site correlates with
the decrease in the relaxation rates via Raman process what is
manifested in lower Cram values. At the same time there is no
decrease in g-anisotropy which suggests that molecular ﬂexibility is
the factor that is responsible for modulations of the vibrations of the
cluster buried in protein matrix. The lower Cram values for samples
with FeS in close contact with cyt b suggest that the increase in the
structural rigidity of the protein environment around the cluster is
caused by interaction of the FeS with other subunits. Observation that
spin–lattice relaxation changes upon the shift of the FeS density at the
Qo provides an additional means of monitoring the FeS movement
which is complementary to our previously reported method based on
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Coenzyme Q10 is a lipophilic antioxidant and cell-growth regula-
tor. It inﬂuences both proliferation and programmed cell death, but
the main function is transferring electrons in mitochondrial respira-
tory chain and hence ATP production [1]. CoQ10 biosynthesis defects
lead to CoQ10 concentration decrease and thus CoQ10 deﬁciency. This
serious disorder has heterogeneous phenotype — mostly encepha-
lopathy, myopathy or renal failure [2].
The aim of the study was characterization of primary CoQ10
deﬁciency in vitro. The model was created using 4-aminobenzoic acid
(PABA) — a competitive inhibitor of polyprenyl-4-hydroxybenzoat
transferase (Coq2p), which is a key enzyme in the CoQ10 biosynthesis
[3].
Three primary cell cultures of human skin ﬁbroblasts (HSF)
acquired from healthy controls and HEK293 cell line were used as a
model for this project.
Four-day incubation of HSF or HEK293 in cultivation medium
(without FBS added) with 1 mM PABA caused signiﬁcant decrease in
CoQ10 concentration (60% or 40% resp. compared to control cells). The
CoQ10-deﬁcient cells were viable. No changes in mitochondrial
morphology and ultrastructure were observed.
Mitochondrial respiratory chain function was changed in the
CoQ10-deﬁcient cells — the activity of NADH:cytochrome c reductase
and succinate: cytochrome c reductase was decreased to 70% of
control-cell activity. Production of reactive oxygen species (ROS) was
increased (based on ﬂuorescent staining, dihydroethidium). Addition
of decylubiquinone to PABA-containing medium (6 μM, 24 h) in-
creased activity of both enzymes signiﬁcantly; the ROS production
was decreased to control levels.
The CoQ10 deﬁciency model using primary cell cultures was
established. This model is highly convenient for further CoQ10
deﬁciency studies, its diagnostics and therapy in human medicine.
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Nitric oxide (NO) plays central roles through its binding to the
heme group of guanylate cyclase that produces cGMP, and it is able to
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